Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
株式のランク #89
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
株価
$47.55
最終同期: 2026-08-12
時価総額
$211.25B
変化(1日)
-2.51%
変化(1年)
-6.99%
DK
取引 Novo Nordisk A/S (NOVO-B)

カテゴリー

Novo Nordisk A/S(NOVO-B)の配当利回りの履歴
Novo Nordisk A/S(銘柄コード: NOVO-B)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Novo Nordisk A/S(NOVO-B)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)
企業 配当利回り
0.56%
US
2.04%
US
2.72%
US
2.69%
CH
2.58%
US